Epidyolex (Cannabidiol)

Prescription oral solution for severe epilepsy syndromes

Rx - Prescription Only Antiepileptic
Active Ingredient
Cannabidiol (CBD)
Dosage Form
Oral solution 100 mg/ml
Manufacturer
Jazz Pharmaceuticals
Brand Names
Epidyolex (EU), Epidiolex (US)
Medically reviewed | Last reviewed: | Evidence level: 1A
Epidyolex is a prescription medicine containing cannabidiol (CBD), a highly purified plant-derived cannabinoid. It is used as an add-on therapy for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome (both in combination with clobazam), and tuberous sclerosis complex (TSC). Approved for patients aged 2 years and older, Epidyolex represents the first pharmaceutical-grade cannabidiol product authorised for use in epilepsy in Europe and the United States.
📅 Published: | Updated:
Reading time: 15 minutes
Written and reviewed by iMedic Medical Editorial Team | Specialists in neurology and pharmacology

Quick facts about Epidyolex

Active Ingredient
Cannabidiol
Plant-derived CBD
Drug Class
Antiepileptic
Cannabinoid-based
Available Forms
Oral Solution
100 mg/ml
Approved Indications
3 conditions
Dravet, LGS, TSC
Prescription Status
Rx Only
Prescription required
Minimum Age
2 years
Children and adults

Key takeaways about Epidyolex

  • Highly purified pharmaceutical CBD: Epidyolex is not the same as over-the-counter CBD oils; it is a rigorously tested, pharmaceutical-grade medicine with proven efficacy in clinical trials
  • Liver monitoring required: Blood tests to check liver function are needed before starting and during treatment, as Epidyolex can cause elevated liver enzymes
  • Used for rare epilepsy syndromes: Approved specifically for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients 2 years and older
  • May cause drowsiness: Do not drive or operate machinery until you know how Epidyolex affects you; drowsiness is one of the most common side effects
  • Do not stop abruptly: Sudden discontinuation may increase seizure frequency; always reduce the dose gradually under medical supervision

What Is Epidyolex and What Is It Used For?

Epidyolex is a prescription oral solution containing cannabidiol (CBD), used as an adjunctive treatment for seizures in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex (TSC). It is approved for adults and children aged 2 years and older.

Epidyolex contains cannabidiol, a naturally occurring compound derived from the Cannabis sativa plant. Unlike tetrahydrocannabinol (THC), cannabidiol does not produce psychoactive effects or a sensation of being "high." Epidyolex is manufactured under strict pharmaceutical standards to ensure consistent purity and potency, distinguishing it clearly from unregulated CBD supplements available over the counter.

The medicine is indicated for three specific epilepsy-related conditions, all of which are characterised by seizures that are often difficult to control with conventional antiepileptic drugs:

  • Dravet syndrome: A rare and severe form of epilepsy that begins in infancy, typically before the age of one year. Seizures are often triggered by fever and are notoriously resistant to standard treatments. Epidyolex is used in combination with clobazam for this condition.
  • Lennox-Gastaut syndrome (LGS): A severe childhood-onset epilepsy characterised by multiple seizure types, cognitive impairment, and a distinctive pattern on electroencephalography (EEG). Epidyolex is used in combination with clobazam for LGS.
  • Tuberous sclerosis complex (TSC): A genetic disorder that causes non-cancerous tumours to grow in the brain and other organs. Epilepsy affects up to 85% of individuals with TSC and often begins in early childhood. Epidyolex is used alongside other antiepileptic medicines for TSC-associated seizures.

The precise mechanism by which cannabidiol exerts its antiseizure effects is not fully understood. Research suggests multiple pathways may be involved, including modulation of intracellular calcium signalling through GPR55 receptors, enhancement of adenosine-mediated signalling, and desensitisation of TRPV1 ion channels. Importantly, cannabidiol does not appear to work through the endocannabinoid CB1 or CB2 receptors, which are the primary targets of THC.

In pivotal clinical trials, Epidyolex demonstrated statistically significant reductions in seizure frequency compared to placebo. In studies of Dravet syndrome, patients receiving Epidyolex experienced a median reduction in convulsive seizure frequency of approximately 39% compared to 13% with placebo. For Lennox-Gastaut syndrome, drop seizure frequency was reduced by approximately 42-44% with Epidyolex versus 17-22% with placebo.

Important distinction:

Epidyolex is a pharmaceutical-grade, highly purified cannabidiol product that has undergone rigorous clinical testing. It should not be confused with commercially available CBD oils, which vary widely in quality, concentration, and purity, and which have not been evaluated in controlled clinical trials for the treatment of epilepsy.

What Should You Know Before Taking Epidyolex?

Before starting Epidyolex, your doctor will assess your liver function and review all other medications you are taking. The medicine should not be used if you are allergic to cannabidiol or have certain liver abnormalities.

Contraindications

Do not take Epidyolex if:

  • You are allergic to cannabidiol or any of the other ingredients in the medicine (including refined sesame oil, ethanol, sucralose, strawberry flavouring, or benzyl alcohol)
  • Your doctor has identified certain abnormal liver enzyme levels in blood tests

If you have a known allergy to sesame seeds or sesame-derived products, inform your doctor before starting treatment, as Epidyolex contains refined sesame oil which in rare cases can cause severe allergic reactions.

Warnings and Precautions

Speak to your doctor or pharmacist before taking Epidyolex, or during treatment, in the following situations:

  • Liver problems: If you have or have had liver disease, your doctor may need to adjust your dose or decide that Epidyolex is not suitable for you. Liver function blood tests are required before starting treatment and will be performed periodically during therapy, as Epidyolex can cause elevated liver enzymes (transaminases). If the liver is not functioning properly, treatment may need to be interrupted or discontinued.
  • Mood and behaviour changes: If you notice unusual changes in mood, behaviour, or if you experience thoughts of self-harm or suicide, contact your doctor or go to a hospital immediately. Antiepileptic medicines as a class have been associated with a small increased risk of suicidal thoughts and behaviour.
  • Drowsiness: Epidyolex may make you drowsy. Do not drive, operate machinery, or engage in activities requiring alertness and good motor coordination (such as cycling) until you know how the medicine affects you.
  • Abrupt discontinuation: Do not suddenly stop taking Epidyolex without consulting your doctor, as this may increase your seizure frequency. Your doctor will explain how to reduce the dose gradually.
  • Increased seizure frequency: If your seizures become more frequent or severe while taking Epidyolex, contact your doctor or seek medical attention immediately.
  • Weight loss: If you lose weight or are unable to gain weight during treatment, your doctor will monitor your weight and assess whether to continue therapy.
Liver function monitoring:

Your doctor must perform blood tests to check your liver function before you start taking Epidyolex and at regular intervals during treatment (typically at 1 month, 3 months, and 6 months after starting, and periodically thereafter). The risk of liver injury is higher in patients who are also taking valproate or clobazam at higher doses. If significant liver enzyme elevations occur, your doctor may need to reduce the dose or discontinue treatment.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using Epidyolex. You should only take Epidyolex during pregnancy if your doctor determines that the benefit of treatment outweighs the potential risk to the foetus.

You should not breastfeed while taking Epidyolex, as cannabidiol is likely to pass into breast milk. The effects of cannabidiol on a breastfed infant are not fully known, and as a precaution, breastfeeding is not recommended during treatment.

Use in Children

Epidyolex is approved for use in children aged 2 years and older. It is not recommended for children under 2 years of age, as the safety and efficacy in this age group have not been established. The medicine contains small amounts of benzyl alcohol and ethanol; use in very young children (under 3 years) for longer than one week should only occur on the recommendation of a healthcare professional.

Driving and Operating Machinery

Epidyolex may cause drowsiness and somnolence, which can impair your ability to drive or operate machinery safely. Discuss with your doctor whether you should drive, and whether children taking the medicine should engage in activities such as cycling or sports. Do not drive, operate machinery, or participate in activities requiring alertness until you are confident that your ability is not impaired.

Important Information About Ingredients

Epidyolex contains several excipients that require awareness:

  • Refined sesame oil: May in rare cases cause severe allergic reactions in individuals sensitive to sesame.
  • Ethanol (alcohol): Each ml contains 79 mg of ethanol (approximately 10% v/v). At the maximum single dose of 12.5 mg/kg, this equates to up to 691.3 mg of ethanol for a 70 kg adult, equivalent to approximately 17 ml of beer or 7 ml of wine per dose. The low amount of alcohol in this medicine is unlikely to produce noticeable effects.
  • Benzyl alcohol: Present in very small quantities (0.0003 mg/ml). Benzyl alcohol may cause allergic reactions. Large amounts can accumulate in the body and cause metabolic acidosis, particularly in individuals with impaired liver or kidney function.

How Does Epidyolex Interact with Other Drugs?

Epidyolex can interact with many other medicines, including common antiepileptic drugs, immunosuppressants, and certain painkillers. Always inform your doctor about all medications you are taking, as dose adjustments may be necessary.

Cannabidiol is metabolised by the liver and can affect the way other medicines are broken down, potentially increasing or decreasing their levels in the blood. Conversely, some medicines can affect the levels of cannabidiol itself. It is essential to tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including herbal preparations. Do not start or stop any medicine without consulting your doctor first.

Major Interactions

The following medicines require particular attention when used with Epidyolex, and dose adjustments may be needed:

Major Drug Interactions with Epidyolex
Drug Category Effect of Interaction Action Required
Clobazam Antiepileptic (benzodiazepine) Epidyolex increases clobazam's active metabolite levels, increasing drowsiness risk Clobazam dose may need to be reduced
Valproate Antiepileptic Increased risk of liver enzyme elevations when used together Closer liver monitoring; possible dose adjustment
Everolimus / Tacrolimus Immunosuppressants (TSC therapy) Epidyolex may increase blood levels of these drugs Monitor drug levels; dose adjustment likely needed
Rifampin Antibiotic May significantly reduce cannabidiol blood levels May reduce Epidyolex effectiveness
St. John's Wort Herbal supplement May reduce cannabidiol blood levels (CYP3A4 induction) Avoid concomitant use
Phenytoin Antiepileptic Epidyolex may increase phenytoin levels Monitor phenytoin levels; dose adjustment may be needed

Other Interactions

The following medicines may also interact with Epidyolex and should be discussed with your doctor:

Other Drug Interactions
Drug Category Nature of Interaction
Carbamazepine Antiepileptic May reduce cannabidiol levels; cannabidiol may increase carbamazepine metabolite
Lamotrigine Antiepileptic Potential for increased lamotrigine levels
Stiripentol Antiepileptic Mutual interaction; dose adjustment may be needed
Morphine / Diflunisal Analgesics Epidyolex may increase levels of these painkillers
Simvastatin / Fenofibrate / Gemfibrozil Lipid-lowering agents Epidyolex may increase statin levels, raising the risk of side effects
Efavirenz Antiretroviral (HIV) May affect cannabidiol metabolism
Theophylline / Caffeine Respiratory / Stimulant Epidyolex may increase theophylline and caffeine levels
Propofol Anaesthetic Epidyolex may increase propofol levels
Enzalutamide Prostate cancer treatment May reduce cannabidiol levels (CYP3A4 induction)
Bupropion Smoking cessation / Antidepressant Epidyolex may increase bupropion levels
Clarithromycin / Erythromycin Antibiotics (macrolides) May increase cannabidiol levels
Food interactions:

Taking Epidyolex with food, particularly high-fat meals, can increase the amount of cannabidiol absorbed into the bloodstream. To maintain consistent effects, try to take the medicine the same way each day — either always with food or always without food, and if taken with food, aim for a similar fat content at each dose.

What Is the Correct Dosage of Epidyolex?

Epidyolex dosage is individualised based on body weight. Treatment typically starts at a low dose that is gradually increased. The maximum recommended dose varies by condition: up to 20 mg/kg/day for Dravet syndrome and LGS, and up to 25 mg/kg/day for TSC.

Always take Epidyolex exactly as your doctor has told you. The dose is calculated based on your body weight and is measured in milligrams per kilogram (mg/kg). Your doctor will start you on a low dose and increase it gradually to find the optimal balance between seizure control and tolerability. Epidyolex is taken twice daily (morning and evening).

Adults and Children (2 Years and Older)

Epidyolex Dosing Schedule
Condition Starting Dose Titration Maintenance Dose Maximum Dose
Dravet syndrome 2.5 mg/kg twice daily (5 mg/kg/day) Increase after 1 week 5 mg/kg twice daily (10 mg/kg/day) 10 mg/kg twice daily (20 mg/kg/day)
Lennox-Gastaut syndrome 2.5 mg/kg twice daily (5 mg/kg/day) Increase after 1 week 5 mg/kg twice daily (10 mg/kg/day) 10 mg/kg twice daily (20 mg/kg/day)
Tuberous sclerosis complex 2.5 mg/kg twice daily (5 mg/kg/day) Increase weekly as tolerated 5 mg/kg twice daily (10 mg/kg/day) 12.5 mg/kg twice daily (25 mg/kg/day)

Patients with Liver Impairment

If you have liver problems, your doctor may need to adjust your dose. Patients with moderate or severe hepatic impairment generally require lower starting doses, slower titration, and lower maximum doses. Your doctor will perform additional liver function monitoring in these cases.

How to Take Epidyolex

Epidyolex is an oral solution that comes with calibrated dosing syringes (1 ml and 5 ml sizes). Your doctor or pharmacist will tell you which syringe to use based on your prescribed dose. Key administration instructions include:

  • Shake the bottle well and use the provided dosing syringe to measure the exact dose
  • Place the syringe tip against the inside of the cheek and push the plunger gently — do not squirt the medicine to the back of the throat
  • For doses exceeding 5 ml, you will need to measure and administer multiple syringe-fulls, keeping careful count
  • If needed, Epidyolex can be administered via a nasogastric or gastrostomy tube — your doctor will provide instructions
  • Clean the syringe after each use by drawing warm soapy water through it, then rinsing and allowing it to air dry completely

Missed Dose

If you miss a dose of Epidyolex, do not take a double dose to make up for it. Simply take the next dose at the usual scheduled time. If you miss multiple doses, speak with your doctor about which dose to take when resuming.

Overdose

If you may have taken more Epidyolex than prescribed, tell your doctor or pharmacist immediately, or go to the nearest emergency department. Bring the medicine with you. Signs of overdose may include diarrhoea and excessive drowsiness.

Do not stop abruptly:

Never reduce your dose or stop taking Epidyolex without first speaking to your doctor. Abrupt discontinuation of antiepileptic medicines may lead to a rebound increase in seizure frequency or severity. Your doctor will instruct you on how to taper the dose gradually if treatment is to be stopped.

What Are the Side Effects of Epidyolex?

Like all medicines, Epidyolex can cause side effects. The most common include drowsiness, diarrhoea, decreased appetite, fever, vomiting, and fatigue. Liver enzyme elevations are a clinically significant side effect that requires monitoring.

Not everyone who takes Epidyolex will experience side effects, but it is important to be aware of them so you can report any concerns to your doctor promptly. Side effects are categorised below by how frequently they occur.

Very Common

May affect more than 1 in 10 people
  • Drowsiness or sleepiness (somnolence)
  • Diarrhoea
  • Decreased appetite
  • Fever (pyrexia)
  • Vomiting
  • Fatigue and lethargy

Common

May affect 1 in 10 to 1 in 100 people
  • Elevated liver enzymes (transaminases) — detected by blood tests
  • Seizures (paradoxical increase in some patients)
  • Irritability and aggression
  • Skin rash
  • Listlessness and lack of energy
  • Cough
  • Pneumonia
  • Weight loss
  • Nausea
  • Urinary tract infection

Frequency Not Known

Cannot be estimated from available data
  • Suicidal thoughts or thoughts of self-harm — seek immediate medical attention if these occur
Seek immediate medical attention if:

You develop signs of liver problems (unexplained nausea, vomiting, abdominal pain, fatigue, loss of appetite, dark urine, or yellowing of the skin or eyes). Also contact your doctor immediately if you experience thoughts of self-harm or suicide, or if your seizures become significantly more frequent or severe.

The risk of liver enzyme elevations appears to be higher in patients who are also taking valproate, in patients receiving higher doses of Epidyolex, and in patients with elevated liver enzymes at baseline. In clinical trials, most cases of liver enzyme elevation were reversible upon dose reduction or discontinuation of treatment.

Drowsiness and sedation are more likely to occur when Epidyolex is used together with clobazam, as cannabidiol increases the blood levels of the active metabolite of clobazam. In some cases, the clobazam dose may need to be reduced to manage this effect.

Weight loss and decreased appetite have been observed, particularly in younger patients. Regular weight monitoring is recommended, especially in children, to ensure adequate nutrition and growth are maintained during treatment.

Reporting side effects:

It is important to report suspected side effects after a medicine has been authorised. This allows continuous monitoring of the benefit-risk balance. Healthcare professionals and patients can report side effects to their national medicines regulatory authority (for example, the MHRA in the UK, BfArM in Germany, or the FDA MedWatch programme in the United States).

How Should You Store Epidyolex?

Epidyolex does not require special storage conditions. Keep it out of reach of children and discard the opened bottle after 12 weeks.

Store Epidyolex in accordance with the following guidelines to ensure the medicine remains effective and safe to use:

  • Temperature: No special temperature requirements — store at room temperature
  • Keep out of reach: Always store the bottle with the child-resistant cap securely fastened, out of the sight and reach of children
  • Expiry date: Do not use Epidyolex after the expiry date printed on the bottle (EXP). The expiry date refers to the last day of that month
  • After opening: Once opened, any solution remaining in the bottle after 12 weeks should be discarded, even if the bottle is not empty
  • Disposal: Do not dispose of Epidyolex via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use, in order to help protect the environment

If the solution in the bottle appears cloudy, this does not affect its effectiveness. Continue to use the medicine as normal. Ensure that the dosing syringe is completely dry before reinserting it into the bottle, as water ingress may cause the solution to appear cloudy.

What Does Epidyolex Contain?

The active substance is cannabidiol at a concentration of 100 mg per ml. Other ingredients include refined sesame oil, ethanol, sucralose, and strawberry flavouring.

Each millilitre of Epidyolex oral solution contains:

  • Active ingredient: Cannabidiol 100 mg
  • Excipients: Refined sesame oil, anhydrous ethanol, sucralose (sweetener), and strawberry flavouring (including benzyl alcohol)

Epidyolex is a clear, colourless to yellow oral solution. It is supplied in a glass bottle with a child-resistant cap. Each pack includes two dosing syringes of the same size (either 1 ml or 5 ml) and two bottle adapters. The 5 ml syringe is graduated in 0.1 ml increments, and the 1 ml syringe in 0.05 ml increments. A spare syringe of each size is included in case the first is lost or damaged.

The marketing authorisation holder for Epidyolex is Jazz Pharmaceuticals Ireland Ltd, Dublin, Ireland. The medicine is manufactured by Jazz Pharmaceuticals Netherlands B.V. in Amersfoort, the Netherlands. For additional information, patients can contact their local representative or the company via email at [email protected].

Frequently Asked Questions About Epidyolex

Epidyolex is used as an add-on treatment for seizures associated with three conditions: Dravet syndrome, Lennox-Gastaut syndrome (both in combination with clobazam), and tuberous sclerosis complex (TSC) in combination with other antiepileptic medicines. It is approved for adults and children aged 2 years and older. It is not a general anti-seizure medication and is specifically indicated for these rare and often treatment-resistant epilepsy syndromes.

No, Epidyolex is fundamentally different from commercially available CBD oils. It is a pharmaceutical-grade, highly purified cannabidiol product manufactured under strict Good Manufacturing Practice (GMP) standards. It has been tested in large-scale randomised controlled clinical trials proving its safety and efficacy. Over-the-counter CBD oils are unregulated, may vary widely in purity and concentration, can contain THC or contaminants, and have not undergone the same rigorous clinical evaluation.

No. Epidyolex contains cannabidiol (CBD), which is a non-psychoactive compound. Unlike THC (tetrahydrocannabinol), the component of cannabis responsible for the "high," CBD does not produce euphoria or psychoactive effects. However, Epidyolex can cause drowsiness and sleepiness, which is a pharmacological side effect rather than a psychoactive effect. This drowsiness may impair your ability to drive or operate machinery.

Epidyolex can cause elevations in liver enzymes (ALT and AST), which may indicate liver stress or damage. This risk is particularly higher when Epidyolex is taken together with valproate or at higher doses. Your doctor will perform liver function blood tests before starting treatment, at approximately 1 month, 3 months, and 6 months, and periodically thereafter. Most cases of liver enzyme elevation in clinical trials were reversible upon dose reduction or discontinuation. Patients with pre-existing liver disease require closer monitoring and potentially lower doses.

If you miss a dose, do not take a double dose to make up for the one you missed. Simply take your next dose at the normal scheduled time. If you miss several doses in a row, contact your doctor for advice on how to resume treatment correctly. Consistency in dosing is important for maintaining stable blood levels of the medicine and optimal seizure control.

Yes, Epidyolex can be taken with or without food. However, taking it with food — particularly high-fat meals — increases the amount of cannabidiol absorbed into the bloodstream. For consistent dosing, it is recommended to take Epidyolex the same way each day. If you take it with food, try to take it with meals of a similar fat content each time. If you are on a ketogenic diet, discuss this with your doctor as the high-fat nature of the diet may affect absorption.

References

  1. European Medicines Agency (EMA). Epidyolex (cannabidiol) – Summary of Product Characteristics. Last updated 2025. Available at: EMA EPAR: Epidyolex
  2. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
  3. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096. doi:10.1016/S0140-6736(18)30136-3
  4. Thiele EA, Bebin EM, Bhathal H, et al. Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol. 2021;78(3):285-292. doi:10.1001/jamaneurol.2020.4607
  5. National Institute for Health and Care Excellence (NICE). Cannabidiol with clobazam for treating seizures associated with Dravet syndrome. Technology appraisal guidance [TA614]. 2019.
  6. National Institute for Health and Care Excellence (NICE). Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome. Technology appraisal guidance [TA615]. 2019.
  7. World Health Organization (WHO). WHO Expert Committee on Drug Dependence: Cannabidiol (CBD) Critical Review Report. 2018.
  8. International League Against Epilepsy (ILAE). Updated Classification of Seizures and Epilepsies. 2017.
  9. U.S. Food and Drug Administration (FDA). Epidiolex (cannabidiol) Prescribing Information. 2018, updated 2024.
  10. Lattanzi S, Brigo F, Trinka E, et al. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 2018;78(17):1791-1804. doi:10.1007/s40265-018-0992-5

Medical Editorial Team

This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed specialists in neurology, pharmacology, and epileptology. All content follows international evidence-based guidelines and the GRADE framework for evaluating medical evidence.

Written by:

iMedic Medical Editorial Team

Specialists in Neurology & Pharmacology

Medical review:

iMedic Medical Review Board

Independent expert review panel

Evidence standard: Level 1A – Based on systematic reviews and randomised controlled trials (Devinsky et al. NEJM 2017, Thiele et al. Lancet 2018, NICE TA614/TA615).
Last medical review:
Guidelines followed: EMA SmPC, FDA Prescribing Information, NICE Technology Appraisals, ILAE Classification